Canivell S, et al. - Researchers conducted a retrospective cohort study with electronic health records from the SIDIAP database (2010-2014) to evaluate glycemic control following treatment intensification (defined as the prescription of any new antidiabetic drug in patients treated with ≥2 non-insulin antidiabetic drugs [NIADS] and HbA1c >7%) in patients with type 2 diabetes uncontrolled on ≥2 NIADS. The most frequently added therapies were insulin and DPP4-inhibitors. According to findings, most patients failed the glycemic goal of HbA1c <7%, in spite of intensification. The reduction was primarily dependent on pre-intensification values of HbA1c, with minor variances between drugs. Findings suggested an association of older age, male gender, higher Charlson index, and short diabetes duration with the achievement of HbA1c <7%.